By Reuters Staff
(Reuters) - The second dose of Pfizer Inc’s COVID-19
vaccine could be delayed in order to cover all priority groups as the first one
is highly protective, two Canada-based researchers said in a letter published
in the New England Journal of Medicine.
The vaccine had an efficacy of 92.6% after
the first dose, Danuta Skowronski and Gaston De Serres said, based on an
analysis of the documents submitted by the drugmaker to the U.S. Food and Drug
Administration (FDA).
These findings were similar to the
first-dose efficacy of 92.1% reported for Moderna Inc's mRNA-1273 vaccine,
according to the letter here
on Wednesday.
In its response, Pfizer said alternative
dosing regimens of the vaccine had not been evaluated yet and that the decision
resided with the health authorities.
Some countries, grappling with low supplies,
are looking at dosing patterns or volumes that differ from how the vaccines
were tested in clinical trials.
There are differences over the merits of
such strategies, with some arguing the urgency of the pandemic requires
flexibility, while others oppose abandoning data-driven approaches for the sake
of expediency.
Skowronski and De Serres cautioned that
there may be uncertainty about the duration of protection with a single dose,
but said the administration of the second dose a month after the first provided
“little added benefit in the short term”.
Skowronski works at the British Columbia
Centre for Disease Control, while De Serres is from the Institut National de
Santé Publique du Québec
In Britain, authorities have said that data
supported its decision to move to a 12-week dosing schedule for Pfizer’s COVID
vaccine. Both Pfizer and partner BioNTech have warned that they had no evidence
to prove it.
Pfizer’s vaccine is authorized to be taken
21 days apart.
The U.S. FDA and the European Medicines
agency have stuck by the interval tested in the trials.
https://www.reuters.com/article/us-health-coronavirus-pfizer/researchers-urge-delaying-pfizer-vaccines-second-dose-as-first-highly-effective-idUSKBN2AI0EC
Pfizer says
South African variant could significantly reduce protective antibodies
February 17, 2021 10:33 PM
(Reuters) -
A laboratory study suggests that the South African variant of the coronavirus
may reduce protective antibodies elicited by the Pfizer Inc/BioNTech SE vaccine
by two-thirds, and it is not clear if the shot will be effective against the
mutation, the companies said on Wednesday.
The study
found the vaccine was still able to neutralize the virus and there is not yet
evidence from trials in people that the variant reduces vaccine protection, the
companies said.
Still, they
are making investments and talking to regulators about developing an updated
version of their mRNA vaccine or a booster shot, if needed.
For the
study, scientists from the companies and the University of Texas Medical Branch
(UTMB) developed an engineered virus that contained the same mutations carried
on the spike portion of the highly contagious coronavirus variant first
discovered in South Africa, known as B.1.351. The spike, used by the virus to
enter human cells, is the primary target of many COVID-19 vaccines.
Researchers
tested the engineered virus against blood taken from people who had been given
the vaccine, and found a two- thirds reduction in the level of neutralizing
antibodies compared with its effect on the most common version of the virus
prevalent in U.S. trials.
Their
findings were published in the New England Journal of Medicine (NEJM).
Because
there is no established benchmark yet to determine what level of antibodies are
needed to protect against the virus, it is unclear whether that two-thirds
reduction will render the vaccine ineffective against the variant spreading
around the world.
However,
UTMB professor and study co-author Pei-Yong Shi said he believes the Pfizer
vaccine will likely be protective against the variant.
“We don’t
know what the minimum neutralizing number is. We don’t have that cutoff line,”
he said, adding that he suspects the immune response observed is likely to be
significantly above where it needs to be to provide protection.
That is
because in clinical trials, both the Pfizer/BioNTech vaccine and a similar shot
from Moderna Inc conferred some protection after a single dose with an antibody
response lower than the reduced levels caused by the South African variant in
the laboratory study.
Even if the
concerning variant significantly reduces effectiveness, the vaccine should
still help protect against severe disease and death, he noted. Health experts
have said that is the most important factor in keeping stretched healthcare
systems from becoming overwhelmed.
More work is
needed to understand whether the vaccine works against the South African
variant, Shi said, including clinical trials and the development of correlates
of protection - the benchmarks to determine what antibody levels are
protective.
Pfizer and
BioNTech said they were doing similar lab work to understand whether their
vaccine is effective against another variant first found in Brazil.
More
https://www.reuters.com/article/us-health-coronavirus-vaccines-variants/pfizer-says-south-african-variant-could-significantly-reduce-vaccine-protection-idUSKBN2AH2VG
Covid-19 Was
Spreading in China Before First Confirmed Cases, Fresh Evidence Suggests
The number,
and genetic sequencing, of the first cases identified by China suggest
coronavirus was spreading before early December 2019
Feb. 19, 2021 5:30 am ET
New evidence from China is affirming what epidemiologists
have long suspected: The coronavirus likely began spreading unnoticed around
the Wuhan area in November 2019, before it exploded in multiple different
locations throughout the city in December.
Chinese authorities have identified 174 confirmed Covid-19 cases around the city from December
2019, said World Health Organization researchers, enough to suggest there were
many more mild, asymptomatic or otherwise undetected cases than previously
thought.
Many of the 174 cases had no known connection to the market
that was initially considered the source of the outbreak, according to
information gathered by WHO investigators during the four-week mission to China
to examine the origins of the virus. Chinese authorities declined to give the WHO team raw data on these cases and
potential earlier ones, team members said.
In examining 13 genetic sequences of the virus from
December, Chinese authorities found similar sequences among those linked to the
market, but slight differences in those of people without any link to it,
according to the WHO investigators. The two sets likely began to diverge
between mid-November and early December, but could possibly indicate infections
as far back as September, said Marion Koopmans, a Dutch virologist on the WHO
team.
More
https://www.wsj.com/articles/covid-19-was-spreading-in-china-before-first-confirmed-cases-fresh-evidence-suggests-11613730600?mod=hp_lead_pos10
Approx. 6 minutes.
Why Are COVID
Fatality Rates Dropping?
https://www.youtube.com/watch?v=fiEk7JJwTT4
Next, some very useful vaccine
links kindly sent along from a LIR reader in Canada. The links come from a most
informative update from Stanford Hospital in California.
World Health Organization -
Landscape of COVID-19 candidate vaccines . https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines
NY Times Coronavirus Vaccine
Tracker . https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html
Stanford Website . https://racetoacure.stanford.edu/clinical-trials/132
FDA information . https://www.fda.gov/media/139638/download
Regulatory Focus COVID-19
vaccine tracker . https://www.raps.org/news-and-articles/news-articles/2020/3/covid-19-vaccine-tracker
Some more useful Covid links.
Johns Hopkins Coronavirus
resource centre
https://coronavirus.jhu.edu/map.html
Rt Covid-19
https://rt.live/
Covid19info.live
https://wuflu.live/
The Spectator
Covid-19 data tracker (UK)
https://data.spectator.co.uk/city/national
Technology Update.
With events happening fast in the development of solar power and
graphene, I’ve added this section. Updates as they get reported. Is converting
sunlight to usable cheap AC or DC energy mankind’s future from the 21st
century onwards.
Vestas
reveals offshore turbine with world's largest sweep
By Paul
Ridden
February 11, 2021
Denmark's Vestas is looking to become an
industry leader in offshore wind, and has introduced the V236-15.0 MW turbine
to take the fight to GE. The new design's blades offer the largest swept area
in the world.
Vestas got into the offshore turbine
business over 25 years ago with the installation of 500-kW V39 units at
Denmark's Tunoe Knob wind farm. The size and energy production capacities of
turbines has grown steadily ever since, with GE Renewable Energy recently
announcing that its world-beating 14-MW
Haliade-X will be part of phase C of the
Dogger Bank offshore wind project due for completion in 2026. Now Vestas has
gone even bigger.
Thanks to
its three 115.5-m (379-ft) blades, the new design is reported to have the
largest swept area in the world, which adds up to 43,742 m2 . It
should be good for sites where wind speeds are high too, with Vestas saying
that it's "rated to withstand IEC 1 extreme wind conditions up to 50 m/s
and IEC T up to 57 m/s."
Each turbine
is expected to deliver around 80 GWh of energy per year, depending on
site-specific conditions, which is said to work out as being enough to power
20,000 European homes.
The
V236-15.0 MW also offers the potential to reduce the number of turbines
deployed at offshore windfarm level – with Vestas calculating that the
"offshore turbine offers 65 percent higher annual energy production than
the V173-9.5 MW, and for a 900-MW wind park it boosts production by five
percent with 34 fewer turbines."
The company
expects the first V236-15.0 MW prototype to be built in 2022, with serial
production following two years later. It has a design lifetime of 25 years.
“With the
V236-15.0 MW, we raise the bar in terms of technological innovation and
industrialization in the wind energy industry, in favor of building
scale," says Anders Nielsen, Vestas CTO. "By leveraging Vestas’
extensive proven technology, the new platform combines innovation with
certainty to offer industry-leading performance while reaping the benefits of
building on the supply chain of our entire product portfolio. The new offshore
platform forms a solid foundation for future products and upgrades.”
https://newatlas.com/energy/vestas-v236-15-mw-offshore-wind-turbine/
Danish wind
turbine maker Vestas lays of 450 employees in U.S. state of Colorado
February 17, 2021 1:19 PM
COPENHAGEN
(Reuters) - Danish wind turbine maker Vestas said on Wednesday it would lay off
450 positions in three factories across Colorado in the United States, as a
result of lower demand.
Vestas said
it expected to offer new roles elsewhere in the business to 150 of the affected
employees.
https://www.reuters.com/article/uk-vestas-layoffs/danish-wind-turbine-maker-vestas-lays-of-450-employees-in-u-s-state-of-colorado-idUSKBN2AH1Q1?il=0
This weekend’s musical diversion. Germany’s highly talented, and very under
recognised, Johann Friedrich Fasch. Today the only music of his that ever gets
airtime now.
Fasch - Concerto for trumpet,
2 oboes, strings & basso continuo a 8 in D major, FWV L:D1
https://www.youtube.com/watch?v=5AOIdtxDQHc
Next, this week’s chess masterclass. Approx. 13 minutes.
No comments:
Post a Comment